Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Sun Yat-sen University

Status and phase: Completed; Phase 2

Conditions: Nasopharyngeal Carcinoma

Treatments: Drug: Anlotinib

Study type: Interventional

Funder types: Other

Identifiers

NCT03906058

B2018-167

Details and patient eligibility

About

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

Enrollment: 39 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• biopsy proved nasopharyngeal carcinoma;
• stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
• 18 years or older; without other malignancy;
• proper functioning of the major organs.

Exclusion criteria

• allergic to anlotinib;
• female within gestation period or lactation;
• patients received drug of other clinical trial within 4 weeks.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

39 participants in 1 patient group

Anlotinib

Experimental group

Treatment:

Drug: Anlotinib